Given the heterogeneity of RP and transcript deregulation in both classical ribosomopathies and sporadic human cancers (Fig 3), it seems likely that other compensatory mutations exist, including those involving p53 and p19ARF inactivation and Mdm2 over-expression. This evidence concerns the gene MDM2 and cancer.